What is Recursion?
Recursion is at the forefront of drug discovery, leveraging a unique blend of biology, chemistry, automation, machine learning, and engineering. The company's core innovation lies in its Recursion Operating System, which generates an expansive proprietary biological and chemical dataset. This dataset, coupled with the Recursion Map, a suite of advanced software and AI tools, enables Recursion to explore complex biological systems and identify novel therapeutic insights, aiming to significantly improve patient outcomes.
How much funding has Recursion raised?
Recursion has raised a total of $514.5M across 10 funding rounds:
Multiple Rounds
$4.9M
Series A
$15M
Debt
$4M
Series B
$60M
Other Financing Round
$20.5M
Series C
$121M
Series D
$239M
Other Financing Round
$50M
Debt (2015): $830K, investors not publicly disclosed
Unspecified (2015): $1.5M led by National Institutes of Health
Angel/Seed (2015): $2.6M supported by Advantage Capital Partners
Series A (2016): $15M featuring Wild Basin Investments, Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, and Lux Capital
Debt (2017): $4M backed by Square 1 Bank
Series B (2017): $60M with participation from Data Collective
Other Financing Round (2018): $20.5M led by Square 1 Bank
Series C (2019): $121M supported by Menlo Ventures, AME Cloud Ventures, Scottish Mortgage Investment Trust PLC, Epic Ventures, Felicis Ventures, Lux Capital, Two Sigma Ventures, Data Collective, Obvious Ventures, Texas Tech University System, Mubadala Ventures, Intermountain Ventures, and CRV
Series D (2020): $239M featuring Obvious Ventures, DCVC, EPIC Ventures, Samsara BioCapital, Two Sigma Ventures, Casdin Capital, Lux Capital, Advantage Capital, Intermountain Ventures, Catalio Capital Management, Mubadala, Laurion Capital Management, Leaps by Bayer, Baillie Gifford International, and Felicis Ventures
Other Financing Round (2023): $50M backed by NVIDIA
Key Investors in Recursion
NVIDIA
NVIDIA is a global technology company specializing in GPUs and AI computing solutions, likely investing in Recursion for its advanced AI and data processing capabilities in drug discovery.
Data Collective
Data Collective (DCVC) is a venture capital firm that typically invests in companies leveraging deep technology and data science, aligning with Recursion's AI-driven approach to biology.
Lux Capital
Lux Capital is a venture capital firm focused on investing in technology and science ventures, particularly those at the intersection of physical and biological sciences.
What's next for Recursion?
With a significant influx of capital, Recursion is poised for accelerated growth and expansion of its drug discovery pipeline. The recent major strategic investment signals strong confidence from its backers in the company's innovative approach and its potential to industrialize the drug discovery process. This backing will likely fuel further development of its proprietary datasets and AI-driven exploration tools, enabling Recursion to pursue new therapeutic targets and advance its clinical programs with greater speed and efficiency.
See full Recursion company page
